Table 3.
Clinical characteristics of 50 hepatocellular carcinoma patients, maximum dominant tumor diameter > 6 cm, according to serum gamma glutamyl transpeptidase or alpha-fetoprotein levels
| Parameters | Low GGT ≤ 104, n = 20, median (min-max) | High GGT > 104, n = 28, median (min-max) | P value | Low AFP ≤ 200, n = 36, median (min-max) | High AFP > 200, n = 14, median (min-max) | P value |
| AFP (ng/mL) | 20.1 (0.8-6388) | 45.7 (1.9-12863) | 0.818 | |||
| GGT (IU/L) | 114 (17-1396) | 106 (29-393) | 0.862 | |||
| AST (IU/L) | 76.5 (19-566) | 71 (25-313) | 0.544 | 81 (19-566) | 76 (28-245) | 0.596 |
| Total Bilirubin (mg/dl) | 1.7 (0.23-13.9) | 1.7 (0.38-13.9) | 0.660 | 1.78 (0.23-13.9) | 1.13 (0.38-11.7) | 0.270 |
| MTD (cm) | 8.5 (6.5-22) | 8.5 (6.4-24) | 0.992 | 8.5 (6.4-24) | 8.5 (6.5-22) | 0.896 |
| Microvascular invasion, n (%) | 0.04a | 0.360 | ||||
| Negative | 9 (45) | 5 (18) | 11 (31) | 4 (29) | ||
| Positive | 11 (55) | 23 (82) | 25 (69) | 10 (71) | ||
| Differentiation, n (%) | ||||||
| Well | 11 (55) | 4 (15) | 0.011a | 13 (36) | 3 (21) | 0.324 |
| Moderate | 7 (35) | 18 (64) | 19 (53) | 7 (50) | ||
| Poor | 2 (10) | 6 (21) | 4 (11) | 4 (29) | ||
| Number of nodules | ||||||
| 1 | 10 (50) | 12 (43) | 0.845 | 16 (44) | 6 (43) | 1.000 |
| > 1 | 10 (50) | 16 (57) | 20 (56) | 8 (57) |
a
P < 0.05.
AFP: Alpha-fetoprotein; GGT: Gamma glutamyl transpeptidase; AST: Aspartate aminotransferase; MTD: Maximum dominant tumor diameter.